SSA
PHAT icon

Schonfeld Strategic Advisors’s Phathom Pharmaceuticals PHAT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-15,614
Closed -$173K – 2913
2026
Q1 		$173K Sell
15,614
-15,330
-50% -$194K ﹤0.01% 1776
2025
Q4 		$513K Buy
+30,944
New +$442K ﹤0.01% 1388
2025
Q3 		– Sell
-306,399
Closed -$2.94M – 2484
2025
Q2 		$2.94M Buy
+306,399
New +$1.7M 0.02% 794
2024
Q4 		– Sell
-208,640
Closed -$3.77M – 2298
2024
Q3 		$3.77M Buy
208,640
+40,317
+24% +$563K 0.03% 634
2024
Q2 		$1.73M Buy
168,323
+23,623
+16% +$243K 0.01% 967
2024
Q1 		$1.54M Buy
144,700
+83,700
+137% +$711K 0.01% 1075
2023
Q4 		$557K Buy
61,000
+22,256
+57% +$192K ﹤0.01% 1248
2023
Q3 		$402K Buy
+38,744
New +$531K ﹤0.01% 1259

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Schonfeld Strategic Advisors's PHAT Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 15,614 shares — an estimated $173K sold.

Schonfeld Strategic Advisors first reported a position in PHAT in Q3 2023 and held it in 8 quarters. The position peaked at $3.77M in Q3 2024. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 15,614 Phathom Pharmaceuticals shares in Q2 2026, an estimated $173K.
  • Schonfeld Strategic Advisors first reported a position in Phathom Pharmaceuticals in Q3 2023 and held it in 8 quarters.
  • Schonfeld Strategic Advisors's Phathom Pharmaceuticals position peaked at $3.77M in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.